TG Therapeutics Inc (TGTX)
17.95
+0.23
(+1.30%)
USD |
NASDAQ |
Jun 27, 16:00
17.94
-0.01
(-0.06%)
After-Hours: 20:00
TG Therapeutics Revenue (Annual): 233.66M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 233.66M |
| December 31, 2022 | 2.785M |
| December 31, 2021 | 6.689M |
| December 31, 2020 | 0.152M |
| December 31, 2019 | 0.152M |
| December 31, 2018 | 0.152M |
| December 31, 2017 | 0.152M |
| December 31, 2016 | 0.152M |
| December 31, 2015 | 0.1524M |
| December 31, 2014 | 0.1524M |
| December 31, 2013 | 0.1524M |
| December 31, 2012 | 0.019M |
| December 31, 2011 | |
| December 31, 2010 |
| Date | Value |
|---|---|
| December 31, 2009 | |
| December 31, 2008 | |
| December 31, 2007 | |
| December 31, 2006 | |
| December 31, 2005 | |
| December 31, 2004 | |
| December 31, 2003 | |
| December 31, 2002 | |
| December 31, 2001 | 2.712M |
| December 31, 2000 | 5.359M |
| December 31, 1999 | 1.20M |
| December 31, 1998 | 2.50M |
| December 31, 1997 | 0.10M |
| December 31, 1996 | 0.10M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
0.152M
Minimum
2019
233.66M
Maximum
2023
48.69M
Average
2.785M
Median
2022
Revenue (Annual) Benchmarks
| Eli Lilly and Co | 34.12B |
| Alnylam Pharmaceuticals Inc | 1.828B |
| Cytokinetics Inc | 7.53M |
| Amicus Therapeutics Inc | 399.36M |
| Insmed Inc | 305.21M |